Unleashing the potential of the body’s immune system

Recent advancements in immunotherapies demonstrate the promise of harnessing the body’s immune system to combat complex diseases. Our proprietary gp96 platform leverages the immune stimulatory properties of the heat shock protein gp96 to induce the immune system’s own response against cancer and infectious disease.

How it works

  • Intracellular gp96 is naturally bound to self-antigens (peptides) in the endoplasmic reticulum (ER
  • Stress-events such as necrotic cell death can result in the release of self-antigens bound to gp96.
  • Extracellular gp96 can stimulate the innate immune toll-like receptors 2 and 4 on Antigen Presenting Cells (APCs) to promote activation.
  • Uptake of gp96 antigen complexes via CD91 can lead to processing and presentation to T cells.
  • We’ve engineered gp96 with an immunoglobulin (gp96-Ig) to constitutively transport predefined antigens of interest to APCs that in turn promote an antigen-specific immune response that includes cytotoxic CD8+ T cells, CD4+ T cells, and B cells.

gp96 by the numbers


Clinical Trial Doses Administered


Clinical Targets



Advantages of a gp96-based vaccine

  • Customizable antigen(s) delivery system: gp96 peptide complexes undergo endocytosis mediated by the surface receptor CD91 on APCs.
  • Stimulates APC cytokine production and maturation that promotes presentation of the target antigen(s) to lymphocytes.
  • Potential to generate multivalent responses to address tumor or pathogen heterogeneity.
  • Favorable clinical trial safety profile with the potential for use as a monotherapy or in combination with other approved therapies.

Therapeutic Vaccines in Development

  • Oncology: We are conducting a Phase 2 trial evaluating the safety and efficacy of HS-110 in combination with either nivolumab (Opdivo®), a Bristol-Myers Squibb anti-PD 1 checkpoint inhibitor, or Merck’s anti-PD1 checkpoint inhibitor, pembrolizumab (KEYTRUDA®), for the treatment of patients with advanced NSCLC. Eligible patient populations include individuals in a second line or greater setting, or with pembrolizumab in a front-line maintenance setting.
  • Infectious Disease: Combing the immune-activating properties of gp96 and the T cell co-stimulator OX40L with a customizable antigen expression system, RapidVax is an evolution of the gp96 platform currently in development to generate protective immunity against emerging infectious diseases.